Contemporary treatment options for overactive bladder.
Taylor
Paul H
PH
Department of Family & Preventive Medicine, Emory University, Atlanta, Georgia, USA.
Sussman
David O
DO
D000328:Adult; D000368:Aged; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D003408:Cresols / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D015444:Exercise; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008333:Mandelic Acids / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D010665:Phenylpropanolamine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D015995:Prevalence; D012737:Sex Factors; D000068737:Tolterodine Tartrate; D014481:United States / Q000453:epidemiology; D014549:Urinary Incontinence / Q000191:economics / Q000209:etiology / Q000628:therapy*
D001559:Benzhydryl Compounds; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin